Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Sutro Biopharma, Inc.

NASDAQ: STRO · Life Sciences · 2 alerts · CIK 1382101

Share price
$9.32Close, Nov 16
Market cap
$155M
Shares outstanding
16.6MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Sutro Biopharma, Inc. filings on SEC EDGAR ↗

5:01 PM ET 10-Q
Financial Results

Sutro Biopharma Q3 2026 Results: Net Loss of $31.5M, Loss Narrows

Sutro Biopharma reported a net loss of $108.5 million for the nine months ended September 30, 2026, compared to a $144.3 million loss in the prior year period. Total revenue decreased significantly to $33.5 million from $90.8 million year-over-year, while operating expenses were reduced through restructuring and lower research and development spending.

Key figure
Net loss $31.5M
4:46 PM ET 8-K
Financial Results

Sutro Biopharma Financial Results

Sutro Biopharma reported third quarter 2026 financial results, highlighting a cash position of $142.2 million which is expected to fund operations into the first half of 2028. The company advanced its clinical pipeline with the first patient dosed in the STRO-006 Phase 1 study and reported progress on its STRO-004 and STRO-227 ADC programs.

Term
3 months

“Over the past year, we have delivered on our commitment to advance our next-generation ADCs with two programs, STRO-004 and STRO-006, entering the clinic in less than a year, and our dual-payload ADC, STRO-227, expected to follow in early 2027.”

Jane Chung, Chief Executive Officer of Sutro

“Early data from STRO-004 give us confidence in its potential to deliver meaningful clinical benefit with our proprietary ADC platform. In addition, our collaboration partner Astellas has initiated patient dosing with a second dual-payload immunostimulatory ADC, further highlighting our strong execution and ability to deliver differentiated, novel dual-payload ADCs.”

Jane Chung, Chief Executive Officer of Sutro

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.